ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia.Cancer cell international · 2021
   Article
2. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.Blood · 2018
   Article

Corrections and comments

• Retraction of
  ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1.2010

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.